See more : Otis Worldwide Corp (4PG.DE) Income Statement Analysis – Financial Results
Complete financial analysis of AN2 Therapeutics, Inc. (ANTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AN2 Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Barksdale Resources Corp. (BRKCF) Income Statement Analysis – Financial Results
- Lundin Mining Corporation (LUNMF) Income Statement Analysis – Financial Results
- Norion Bank AB (NORION.ST) Income Statement Analysis – Financial Results
- Valartis Group AG (0RPP.L) Income Statement Analysis – Financial Results
- Home Control International Limited (1747.HK) Income Statement Analysis – Financial Results
AN2 Therapeutics, Inc. (ANTX)
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 77.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -77.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 54.87M | 29.51M | 16.91M | 6.02M | 4.89M |
| General & Administrative | 14.76M | 12.75M | 4.67M | 1.27M | 1.73M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 287.27K |
| SG&A | 14.76M | 12.75M | 4.67M | 1.27M | 289.00K |
| Other Expenses | 0.00 | -45.00K | -38.00K | -6.32M | 0.00 |
| Operating Expenses | 69.64M | 42.26M | 21.57M | 7.28M | 5.18M |
| Cost & Expenses | 69.64M | 42.26M | 21.57M | 7.28M | 5.18M |
| Interest Income | 0.00 | 1.35M | 69.00K | 3.00K | 0.00 |
| Interest Expense | 0.00 | 514.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 69.64M | 77.00K | 21.57M | 7.28M | 31.07M |
| EBITDA | 4.90M | -42.26M | 0.00 | -6.32M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -69.64M | -42.26M | -21.57M | -7.28M | -5.18M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.90M | 1.31M | 31.00K | -6.32M | -457.00K |
| Income Before Tax | -64.73M | -40.96M | -21.54M | -13.60M | -5.64M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 514.00K | -69.00K | -3.00K | -31.07K |
| Net Income | -64.73M | -41.47M | -21.47M | -13.60M | -5.64M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.74 | -2.14 | -1.15 | -0.73 | -0.30 |
| EPS Diluted | -2.74 | -2.14 | -1.15 | -0.73 | -0.30 |
| Weighted Avg Shares Out | 23.60M | 19.40M | 18.74M | 18.74M | 18.74M |
| Weighted Avg Shares Out (Dil) | 23.60M | 19.40M | 18.74M | 18.74M | 18.74M |
AN2 Therapeutics Stock to List Today
AN2 Therapeutics Set for a March IPO
Source: https://incomestatements.info
Category: Stock Reports